July 8, 2026 · Blood · DOI: 10.1182/blood.2025031845

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia

Listen to this summary

The authors investigate the role of USP22 in regulating MEIS1 protein stability and gene transcription in KMT2Ar acute leukemia, a subtype associated with poor prognosis and chemotherapy resistance. Through a genome-wide CRISPR/Cas9 screen, they identify USP22 as a crucial deubiquitinase that protects MEIS1 from degradation, thereby promoting leukemogenic transcription. The study suggests that targeting USP22 may offer a novel therapeutic strategy for treating KMT2Ar acute leukemias.

Sarah Bröchtel, Constanze Schneider, Marius Müller, Christina Villinger, Thomas Plenge, Manoj K Gupta, Luca Immanuel Kesel, Sebastian Scheich, Sebastian Wolf, Ali Yavuz Cakir, Björn Häupl, Florian Buettner, Stefan Knapp, Hubert Serve, Kimberly Stegmaier, Florian Perner, Thomas Oellerich, Anjali Cremer

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play